Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.46 |
| ▸ | IDH1 | O75874 | 5/20 | 0.38 |
| ▸ | IDH2 | P48735 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771285 | 0.83 | MALT1 (0.33) | MALT1IDH1IDH2 | |
| SCHEMBL31493027 | 0.83 | MAP4K1 (0.35) | MALT1IDH1IDH2 | |
| SCHEMBL851308 | 0.79 | MALT1 (0.31) | MALT1 | |
| SCHEMBL11097271 | 0.77 | — | — | |
| SCHEMBL393333 | 0.77 | ADORA2A (0.34) | — | |
| SCHEMBL21328933 | 0.74 | MALT1 (0.52) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL3295825 | 0.74 | MALT1 (0.47) | MALT1IDH1IDH2TAS2R14 | |
| SCHEMBL19337822 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL29757680 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL1420222 | 0.73 | NOS3 (0.47) | MALT1IDH1IDH2NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638635-A | Synthesis method of compound 4-hydroxy-2-trifluoromethyl pyrimidine | 上海毕得医药科技股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2013090873-A1 | A COMPOSITION AND METHOD FOR REDUCING CYANURIC ACID IN RECREATIONAL WATER | HAVILAND PRODUCTS COMPANY (US) | 2013-06-20 | — | — | WO | claimed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4539844-A2 | COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION | Trawsfynydd Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119638635-A | Synthesis method of compound 4-hydroxy-2-trifluoromethyl pyrimidine | 上海毕得医药科技股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638635-A | Synthesis method of compound 4-hydroxy-2-trifluoromethyl pyrimidine | 上海毕得医药科技股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638635-A | Synthesis method of compound 4-hydroxy-2-trifluoromethyl pyrimidine | 上海毕得医药科技股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119604290-A | Compounds for the treatment of coronavirus infections | 特劳斯芬尼德治疗股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-3935042-B1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-4151288-A | ANTHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-04-24 | — | — | US | disclosed |
| US-4137237-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4137234-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4018931-A | INHIBITION OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | MALT1 1717/4885IDH1 2320/4885IDH2 2380/4885 |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | MALT1 967/4885IDH1 1442/4885IDH2 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.